Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal HealthBelieves Slate Possesses Necessary Experience in Capital Allocation, Corporate Governance, Pet Healthcare, Supply Chain Management and Succession PlanningContends the Upcoming Annual Meeting is the Ideal Moment to Introduce Truly Independent Directors and Start a Boardroom Dialogue Around a Properly Timed CEO Change in 2025Reminds Shareholders That Elancos Leadership Has Failed to Deliver Value and Meet its Own Promises Over Every Long-Term HorizonUrges Shareholders to Review Presentation Regarding the Case for Shareholder-Driven Change Atop ElancoAncora Holdings Group, LLC (together with its affiliates, Ancora or we), which owns approximately 3% of the outstanding common stock of Elanco Animal Health Incorporated (NYSE: ELAN) (Elanco or the Company), today issued the below statement regarding its nomination of four highly qualified, independent candidates for election to the Companys Board of Directors (the Board) at the 2024 Annual Meeting of Shareholders (the Annual Meeting). It is important to stress that we provided Elanco with a detailed analysis of its issues pertaining to corporate governance, finance, operations and product development, while also privately proposing a settlement framework that accounted for a shareholder-driven refreshment of the Board and an orderly succession process in 2025 for long-serving CEO Jeff Simmons. All of this has translated to negative total shareholder returns over every relevant long-term period, including since inflection points such as the Companys 2018 initial public offering, 2020 acquisition of Bayer Animal Health and 2021 announcement of structural changes to simplify the organization. Lastly, team members such as EVPs Ellen de Brabander, Ph.D. and Tim Bettington are really the key leaders of upcoming launches.As evidenced by our emphasis on the next generation and willingness to have a principal on the Board, we look forward to being a long-term shareholder of Elanco. Previously held various leadership roles during her nearly 30-year tenure at Abbott Laboratories (NYSE: ABT), a multinational medical devices and healthcare company where she most recently led commercial operations for Europe.